Mydecine Innovations Group (MYCO.NE) announced they have signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine. The research will be led by Dr. Matthew Johnson…
Health Science
PharmaCyte Biotech (PMCB.Q) released a statement from Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, on August 16, 2021. In this statement, Mr. Waggoner comments on the Company’s…
Revive Therapeutics (RVV.C) announced they are entering into an exclusive license agreement with Puerto Rico Science Technology and Research Trust (PRSTRT) for the intellectual property titled ‘Biologically Active Ganoderma…
AzurRx BioPharma (AZRX.Q) today announced positive topline results from its Phase 2 Combination Trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy…
Medexus Pharmaceuticals (MDP.T) today announced its financial results and provided a business update for the three-month period ended June 30, 2021. “We continued to see pressure on IXINITY® ex-factory…
Aequus Pharmaceuticals (AQS.V) and reVision Therapeutics today announced a collaboration on the development of a therapy for Stargardt disease. The agreement will provide the Company with the option to…
Cybin (CYBN.NE) announced they are filing a new non-provisional patent application, their 14th patent application. The decision comes after what they called “a favourable international search report” relating to…
Doubling down on Cybin Back in January, Horizons’ (PYSK.NE) ETF held a relatively balanced portfolio of psychedelics companies. No company made up more than 10% of its holdings, with…
Valeo Pharma (VPH.C) announced today that it has completed implementation of its new corporate structure and launched full commercial activities in support of Enerzair Breezhaler triple therapy and Atectura…
Filament Health (FH.NE) to release their unaudited financial results for the second quarter of 2021, a period that ended June 30, 2021. As of June 30, Filament had $7.8…